The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease

Purpose: Enzyme replacement therapy with rhGAA (Myozyme®) has lead to improved survival, which is largely attributable to improvements in cardiomyopathy and skeletal muscle function. However, crossreactive immunologic material-negative patients have a poor clinical response to enzyme replacement therapy secondary to high sustained antibody titers. Furthermore, although the majority of crossreactive immunologic material-positive patients tolerize or experience a downtrend in anti-rhGAA antibody titers, antibody response is variable with some crossreactive immunologic material-positive infants also mounting high sustained antibody titers.Methods: We retrospectively analyzed 34 infants with Pompe disease: 11 crossreactive immunologic material-negative patients, nine high-titer crossreactive immunologic material-positive patients, and 14 low-titer crossreactive immunologic material-positive patients. Clinical outcome measures were overall survival, ventilator-free survival, left ventricular mass index, Alberta Infant Motor Scale score, and urine Glc4 levels.Results: Clinical outcomes in the high-titer crossreactive immunologic material-positive group were poor across all areas evaluated relative to the low-titer crossreactive immunologic material-positive group. For the crossreactive immunologic material-negative and high-titer crossreactive immunologic material-positive groups, no statistically significant differences were observed for any outcome measures, and both patient groups did poorly.Conclusions: Our data indicate that, irrespective of crossreactive immunologic material status, patients with infantile Pompe disease with high sustained antibody titer have an attenuated therapeutic response to enzyme replacement therapy. With the advent of immunomodulation therapies, identification of patients at risk for developing high sustained antibody titer is critical.

[1]  N. Casadevall Antibodies against rHuEPO: native and recombinant. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  J. Clancy,et al.  Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease , 2009, Pediatric Research.

[3]  T. Choudhury,et al.  Glycogen storage disease (type-III). , 1991, Indian pediatrics.

[4]  B. Byrne,et al.  Recombinant human acid α-glucosidase , 2007, Neurology.

[5]  C. Kempton,et al.  How we treat a hemophilia A patient with a factor VIII inhibitor. , 2009, Blood.

[6]  J. Darrah,et al.  Motor Assessment of the Developing Infant , 1994 .

[7]  B. Thurberg,et al.  Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. , 2007, Molecular genetics and metabolism.

[8]  J. Belmont,et al.  Enzyme-replacement therapy in mucopolysaccharidosis I. , 2001, The New England journal of medicine.

[9]  T. Voit,et al.  Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial , 2005, Neuromuscular Disorders.

[10]  W. Hoots,et al.  Advances in hemophilia: experimental aspects and therapy. , 2010, Hematology/oncology clinics of North America.

[11]  Yuan-Tsong Chen,et al.  Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry. , 2003, Analytical biochemistry.

[12]  A. Rosenberg,et al.  Elimination of antibodies to recombinant enzyme in Pompe's disease. , 2009, The New England journal of medicine.

[13]  D. Millington,et al.  Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. , 2000, Analytical biochemistry.

[14]  H. Mandel,et al.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. , 2010, Molecular genetics and metabolism.

[15]  A. Pestronk,et al.  A randomized study of alglucosidase alfa in late-onset Pompe's disease. , 2010, The New England journal of medicine.

[16]  D. Brooks,et al.  Enzyme Replacement Therapy in Mucopolysaccharidosis I: Altered Distribution and Targeting of α-l-Iduronidase in Immunized Rats , 2000 .

[17]  M. Vogel,et al.  Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children , 1991, Pediatric Cardiology.

[18]  M. Kroos,et al.  High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. , 2010, Molecular genetics and metabolism.

[19]  J. Charrow,et al.  Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial , 2001, Genetics in Medicine.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  M. Knip,et al.  Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. , 1988, Diabetes research.

[22]  D. Koeberl,et al.  Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. , 2007, American journal of human genetics.

[23]  S. Marie,et al.  Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: “To See a World in a Grain of Sand…” , 2007, Autophagy.

[24]  C. Rougeot,et al.  Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. , 1991, Hormone research.

[25]  Wuh-Liang Hwu,et al.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[26]  C. Wanner,et al.  Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. , 2008, Molecular genetics and metabolism.

[27]  J. McPherson,et al.  Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. , 1993, Blood.

[28]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[29]  S. Richards Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders , 2002 .

[30]  M. Mcentee,et al.  Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. , 2008, The Journal of clinical investigation.

[31]  B. Byrne,et al.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. , 2007, Neurology.

[32]  R. Herndon,et al.  Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis , 1998, Neurology.

[33]  G. Herman,et al.  Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[34]  G. Hug Pre- and postnatal pathology, enzyme treatment, and unresolved issues in five lysosomal disorders. , 1978, Pharmacological reviews.

[35]  N. Raben,et al.  Induction of Tolerance to a Recombinant Human Enzyme, Acid Alpha-Glucosidase, in Enzyme Deficient Knockout Mice , 2003, Transgenic Research.

[36]  B. Byrne,et al.  Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease , 2009, Genetics in Medicine.

[37]  C. Hollak,et al.  Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? , 2009, Molecular genetics and metabolism.

[38]  S Porter,et al.  Human immune response to recombinant human proteins. , 2001, Journal of pharmaceutical sciences.